Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Duke Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer.
Journal article Prostate Cancer Prostatic Dis · October 2026 BACKGROUND: In ARAMIS, darolutamide statistically significantly prolonged metastasis-free survival by 2 years and reduced the risk of death by 31% in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We report post hoc analyses of ... Full text Link to item CitePhase I design for partially ordered groups with late-onset toxicity.
Journal article Clin Trials · October 2026 BACKGROUND: In this article, we introduce a Phase I clinical trial design that utilizes late-onset toxicity outcomes to determine group-specific doses when groups are partially ordered before the trial. By "partially ordered groups," we mean that the frail ... Full text Link to item CitePatterns of Poly(ADP-Ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans With Prostate Cancer.
Journal article Clin Genitourin Cancer · October 2026 BACKGROUND: PARP inhibitors are life-prolonging therapies for men with homologous recombination repair (HRR) deficient mCRPC. Estimates of PARPi benefit in diverse patient populations are limited. Here we describe patterns of PARPi use and outcomes in mCRP ... Full text Link to item CiteRecent Grants
Prostate Cancer Research Program Clinical Consortium Award
ResearchCo Investigator · Awarded by Department of Defense · 2026 - 2030The COVID-19 and Cancer Consortium (CCC19) Registry
ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028View All Grants
Education
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.